

Christopher J Pepper

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8906164/publications.pdf>

Version: 2024-02-01

137
papers

4,155
citations

117453

34
h-index

118652

62
g-index

137
all docs

137
docs citations

137
times ranked

6132
citing authors

#	ARTICLE	IF	CITATIONS
1	Combined analysis of IGHV mutations, telomere length and CD49d identifies long-term progression-free survivors in TP53 wild-type CLL treated with FCR-based therapies. <i>Leukemia</i> , 2022, 36, 271-274.	3.3	4
2	Long-term follow-up of 415 patients with chronic lymphocytic leukemia treated with fludarabine and cyclophosphamide-based chemoimmunotherapy in the frontline <sc>ADMIRE</sc> and <sc>ARCTIC</sc> trials: A comprehensive assessment of prognostic factors. <i>American Journal of Hematology</i> , 2022, 97, .	2.0	1
3	Efficacy of MDX-124, a novel anti-annexin-A1 antibody, in preclinical models of pancreatic cancer.. <i>Journal of Clinical Oncology</i> , 2022, 40, 590-590.	0.8	0
4	Abstract P5-08-06: MDX-124, a novel annexin-A1 antibody, shows anti-tumor efficacy in several preclinical models of triple-negative breast cancer. <i>Cancer Research</i> , 2022, 82, P5-08-06-P5-08-06.	0.4	0
5	Elucidation of Focal Adhesion Kinase as a Modulator of Migration and Invasion and as a Potential Therapeutic Target in Chronic Lymphocytic Leukemia. <i>Cancers</i> , 2022, 14, 1600.	1.7	6
6	Targeting the Non-Canonical NF- κ B Pathway in Chronic Lymphocytic Leukemia and Multiple Myeloma. <i>Cancers</i> , 2022, 14, 1489.	1.7	6
7	Novel pyrrolobenzodiazepine benzofused hybrid molecules inhibit NF- κ B activity and synergise with bortezomib and ibrutinib in hematological cancers. <i>Haematologica</i> , 2021, 106, 958-967.	1.7	4
8	Genome-wide association study identifies risk loci for progressive chronic lymphocytic leukemia. <i>Nature Communications</i> , 2021, 12, 665.	5.8	9
9	Structure-based design of highly selective 2,4,5-trisubstituted pyrimidine CDK9 inhibitors as anti-cancer agents. <i>European Journal of Medicinal Chemistry</i> , 2021, 214, 113244.	2.6	10
10	Single Diastereomers of the Clinical Anticancer ProTide Agents NUC-1031 and NUC-3373 Preferentially Target Cancer Stem Cells <i>In Vitro</i>. <i>Journal of Medicinal Chemistry</i> , 2021, 64, 8179-8193.	2.9	10
11	TLR9 expression in chronic lymphocytic leukemia identifies a promigratory subpopulation and novel therapeutic target. <i>Blood</i> , 2021, 137, 3064-3078.	0.6	20
12	Proteomics-based identification of cancer-associated proteins in chronic lymphocytic leukaemia. <i>Electronic Journal of Biotechnology</i> , 2021, 52, 1-12.	1.2	1
13	Abstract 1874: MDX-124, a novel annexin-A1 antibody, induces an anti-tumor immune response and wide-ranging anti-cancer activity in multiple preclinical models. , 2021, , .		1
14	<i>TP53</i> Mutations with Low Variant Allele Frequency Predict Short Survival in Chronic Lymphocytic Leukemia. <i>Clinical Cancer Research</i> , 2021, 27, 5566-5575.	3.2	23
15	Increased frequency of CD4⁺PDα⁺HLAα^{DR} T cells is associated with disease progression in CLL. <i>British Journal of Haematology</i> , 2020, 188, 872-880.	1.2	18
16	<p>Transcriptomics-Based Characterization of the Toxicity of ZnO Nanoparticles Against Chronic Myeloid Leukemia Cells</p>. <i>International Journal of Nanomedicine</i> , 2020, Volume 15, 7901-7921.	3.3	22
17	Dissecting the role of the CXCL12/CXCR4 axis in acute myeloid leukaemia. <i>British Journal of Haematology</i> , 2020, 189, 815-825.	1.2	23
18	CD49d promotes disease progression in chronic lymphocytic leukemia: new insights from CD49d bimodal expression. <i>Blood</i> , 2020, 135, 1244-1254.	0.6	33

#	ARTICLE	IF	CITATIONS
19	Clinical utility of telomere length measurements in cancer. <i>Current Opinion in Genetics and Development</i> , 2020, 60, 107-111.	1.5	4
20	A laboratory-based scoring system predicts early treatment in Rai 0 chronic lymphocytic leukemia. <i>Haematologica</i> , 2020, 105, 1613-1620.	1.7	15
21	Telomere Length and CD49d Cooperate with IGHV Gene Status As Predictors of Long-Term Progression-Free Survival in CLL Patients Treated with FCR-Based Regimens. <i>Blood</i> , 2020, 136, 46-47.	0.6	0
22	Targeting CDK9 for treatment of colorectal cancer. <i>Molecular Oncology</i> , 2019, 13, 2178-2193.	2.1	39
23	Effects of Systematic Shortening of Noncovalent C8 Side Chain on the Cytotoxicity and NF- κ B Inhibitory Capacity of Pyrrolobenzodiazepines (PBDs). <i>Journal of Medicinal Chemistry</i> , 2019, 62, 2127-2139.	2.9	17
24	Telomere length predicts for outcome to FCR chemotherapy in CLL. <i>Leukemia</i> , 2019, 33, 1953-1963.	3.3	12
25	Activation of naïve CD4+ T cells re-tunes STAT1 signaling to deliver unique cytokine responses in memory CD4+ T cells. <i>Nature Immunology</i> , 2019, 20, 458-470.	7.0	32
26	Telomere fusions associate with coding sequence and copy number alterations in CLL. <i>Leukemia</i> , 2019, 33, 2093-2097.	3.3	9
27	Is venetoclax a new wonder drug in CLL?. <i>British Journal of Haematology</i> , 2019, 185, 643-646.	1.2	0
28	Genetic correlation between multiple myeloma and chronic lymphocytic leukaemia provides evidence for shared aetiology. <i>Blood Cancer Journal</i> , 2019, 9, 1.	2.8	40
29	Multicentre Genome Wide Association Study Identifies Risk Alleles for Progressive Chronic Lymphocytic Leukaemia. <i>Blood</i> , 2019, 134, 1740-1740.	0.6	1
30	Hydroxybenzoate magnesium analogues induced apoptosis in HT-1080 human fibrosarcoma cells. <i>Clinical Sciences Research and Reports</i> , 2019, 2, .	0.2	0
31	Abstract 9: Effect of C8-side chain on the cytotoxicity and NF- κ B inhibitory capacity of pyrrolobenzodiazepines. , 2019, , .		0
32	Abstract 9: Effect of C8-side chain on the cytotoxicity and NF- κ B inhibitory capacity of pyrrolobenzodiazepines. , 2019, , .		1
33	Inhibitory- κ B Kinase (IKK) β and Nuclear Factor- κ B (NF- κ B)-Inducing Kinase (NIK) as Anti-Cancer Drug Targets. <i>Cells</i> , 2018, 7, 176.	1.8	49
34	PARP inhibition prevents escape from a telomere-driven crisis and inhibits cell immortalisation. <i>Oncotarget</i> , 2018, 9, 37549-37563.	0.8	4
35	Chapter 5. Small Molecule Inhibitors of NF- κ B and Their Therapeutic Potential in Leukaemia. <i>RSC Drug Discovery Series</i> , 2018, , 125-146.	0.2	0
36	Telomere Length Is Associated with Epigenetic Programming in CLL and Is a Superior Predictor of Clinical Outcome with the Ability to Bifurcate Patients with the Same CLL-IPI Score. <i>Blood</i> , 2018, 132, 1833-1833.	0.6	0

#	ARTICLE	IF	CITATIONS
37	A Laboratory Based Scoring System Predicts Early Treatment in Rai 0/Binet a CLL. Blood, 2018, 132, 4399-4399.	0.6	0
38	Development and Characterisation of an in Vitro Model of Multiple Myeloma. Blood, 2018, 132, 4505-4505.	0.6	0
39	Telomere Length Predicts for Outcome to FCR Chemoimmunotherapy in CLL. Blood, 2018, 132, 1854-1854.	0.6	0
40	Genome-wide association analysis of chronic lymphocytic leukaemia, Hodgkin lymphoma and multiple myeloma identifies pleiotropic risk loci. Scientific Reports, 2017, 7, 41071.	1.6	31
41	Genome-wide association analysis implicates dysregulation of immunity genes in chronic lymphocytic leukaemia. Nature Communications, 2017, 8, 14175.	5.8	75
42	Telomere length is an independent prognostic marker in <sc>MDS</sc> but not in <i>de novo</i> </sc>AML</sc>. British Journal of Haematology, 2017, 178, 240-249.	1.2	21
43	Telomere length is a critical determinant for survival in multiple myeloma. British Journal of Haematology, 2017, 178, 94-98.	1.2	26
44	Tumor cell migration is inhibited by a novel therapeutic strategy antagonizing the alpha-7 receptor. Oncotarget, 2017, 8, 11414-11424.	0.8	14
45	Key Molecular Drivers of Chronic Lymphocytic Leukemia. Clinical Lymphoma, Myeloma and Leukemia, 2016, 16, 593-606.	0.2	15
46	Phenotype and immune function of lymph node and peripheral blood CLL cells are linked to transendothelial migration. Blood, 2016, 128, 563-573.	0.6	27
47	Cytomegalovirus infection does not impact on survival or time to first treatment in patients with chronic lymphocytic leukemia. American Journal of Hematology, 2016, 91, 776-781.	2.0	14
48	Abstract LB-113: Antihormone-induced expression of BCL3 in estrogen receptor-positive breast cancer drives resistant cell growth. , 2016, , .		0
49	In Vitro Co-Culture of CLL-B Cells Reveals Long-Term Survival, Proliferation, and Maintenance of Telomere Length. Blood, 2016, 128, 350-350.	0.6	1
50	Genetic Analysis of Distinct Phenotypic Subsets within MM1.S Multiple Myeloma Cell Line Reveals the Pre-Existence of MM.1R-like Glucocorticoid Resistance and a Sub-Clone with an Activating PI3-Kinase Delta Mutation That Is Preferentially Sensitive to the Selective PI3-Kinase Inhibitor, Idelalisib. Blood, 2016, 128, 4449-4449.	0.6	0
51	A CD21 low phenotype, with no evidence of autoantibodies to complement proteins, is consistent with a poor prognosis in CLL. Oncotarget, 2015, 6, 32669-32680.	0.8	6
52	Understanding cancer cell survival is key to patient survival. Lancet Oncology, The, 2015, 16, 122-124.	5.1	20
53	<sc>CD</sc>8⁺ Tâ€cell recognition of a synthetic epitope formed by <i>t</i>â€butyl modification. Immunology, 2015, 144, 495-505.	2.0	1
54	The effect of hydroxybenzoate calcium compounds in inducing cell death in epithelial breast cancer cells. Advances in Modern Oncology Research, 2015, 1, .	0.1	2

#	ARTICLE	IF	CITATIONS
55	Abstract 4555: C8-linked pyrrolobenzodiazepine (PBD)-benzofused hybrids as transcription factor inhibitors. , 2015, , .		0
56	Morphological modulation of human fibrosarcoma HT-1080 cells by hydroxybenzoate compounds during apoptosis. <i>Advances in Modern Oncology Research</i> , 2015, 1, 68.	0.1	0
57	Targeting RNA transcription and translation in ovarian cancer cells with pharmacological inhibitor CDKI-73. <i>Oncotarget</i> , 2014, 5, 7691-7704.	0.8	48
58	Telomere analysis to predict chronic lymphocytic leukemia outcome: a STELA test to change clinical practice?. <i>Expert Review of Hematology</i> , 2014, 7, 701-703.	1.0	4
59	Telomere dysfunction accurately predicts clinical outcome in chronic lymphocytic leukaemia, even in patients with early stage disease. <i>British Journal of Haematology</i> , 2014, 167, 214-223.	1.2	73
60	Development and characterization of a physiologically relevant model of lymphocyte migration in chronic lymphocytic leukemia. <i>Blood</i> , 2014, 123, 3607-3617.	0.6	31
61	A genome-wide association study identifies multiple susceptibility loci for chronic lymphocytic leukemia. <i>Nature Genetics</i> , 2014, 46, 56-60.	9.4	166
62	Proteomics-Based Strategies To Identify Proteins Relevant to Chronic Lymphocytic Leukemia. <i>Journal of Proteome Research</i> , 2014, 13, 5051-5062.	1.8	33
63	Small-Molecule Inhibitors of 25-Hydroxyvitamin D-24-Hydroxylase (CYP24A1): Synthesis and Biological Evaluation. <i>Journal of Medicinal Chemistry</i> , 2014, 57, 7702-7715.	2.9	17
64	CD49d Is the Strongest Flow Cytometryâ€‘Based Predictor of Overall Survival in Chronic Lymphocytic Leukemia. <i>Journal of Clinical Oncology</i> , 2014, 32, 897-904.	0.8	162
65	A novel Cdk9 inhibitor preferentially targets tumor cells and synergizes with fludarabine. <i>Oncotarget</i> , 2014, 5, 375-385.	0.8	73
66	Abstract 1630: C8-linked pyrrolobenzodiazepine (pbd)-benzofused conjugates with low-picomolar in vitro cytotoxicity. , 2014, , .		0
67	CLL Is Associated with Development of Subclinical Cytomegalovirus Viraemia and Accumulation of Large Populations of â€œexhaustedâ€‘CMV-Specific CD4+ T Cells. <i>Blood</i> , 2014, 124, 3290-3290.	0.6	0
68	CXCL12 Enhances CLL Cell and T-Cell Migration in a Dynamic Circulating Model of CLL That Can be Abrogated By the CXCR4 Antagonist ONO-7161. <i>Blood</i> , 2014, 124, 3293-3293.	0.6	0
69	An Assessment of Calcium Handling and Cardiovascular Drug-Profiling in Cytiva Embryonic Stem-Cell Derived Cardiomyocytes. <i>Biophysical Journal</i> , 2013, 104, 604a.	0.2	0
70	Apoptosis Deregulation in CLL. <i>Advances in Experimental Medicine and Biology</i> , 2013, 792, 151-171.	0.8	8
71	Comparative Structural and Functional Studies of 4-(Thiazol-5-yl)-2-(phenylamino)pyrimidine-5-carbonitrile CDK9 Inhibitors Suggest the Basis for Isotype Selectivity. <i>Journal of Medicinal Chemistry</i> , 2013, 56, 660-670.	2.9	51
72	GC-Targeted C8-Linked Pyrrolobenzodiazepineâ€‘Biaryl Conjugates with Femtomolar in Vitro Cytotoxicity and in Vivo Antitumor Activity in Mouse Models. <i>Journal of Medicinal Chemistry</i> , 2013, 56, 2911-2935.	2.9	50

#	ARTICLE	IF	CITATIONS
73	Substituted 4-(Thiazol-5-yl)-2-(phenylamino)pyrimidines Are Highly Active CDK9 Inhibitors: Synthesis, X-ray Crystal Structures, Structure-Activity Relationship, and Anticancer Activities. <i>Journal of Medicinal Chemistry</i> , 2013, 56, 640-659.	2.9	111
74	Pharmacological Importance of Simple Phenolic Compounds on Inflammation, Cell Proliferation and Apoptosis with a Special Reference to Î²-D-Salicin and Hydroxybenzoic Acid. <i>European Journal of Inflammation</i> , 2013, 11, 327-336.	0.2	17
75	The <sc>HSP</sc>90 inhibitor <sc>NVP</sc>-<sc>AUY</sc>922<sc>AG</sc> inhibits the <sc>PI</sc>3K and <sc>IKK</sc> signalling pathways and synergizes with cytarabine in acute myeloid leukaemia cells. <i>British Journal of Haematology</i> , 2013, 161, 57-67.	1.2	25
76	Blinatumomab induces autologous T-cell killing of chronic lymphocytic leukemia cells. <i>Haematologica</i> , 2013, 98, 1930-1938.	1.7	64
77	The Effect of Hydroxybenzoate Lithium Complexes in Inducing Apoptosis in HT-1080 Human Fibrosarcoma Cells. <i>Journal of Cancer Research</i> , 2013, 2013, 1-8.	0.7	2
78	Abstract 1129: GC-t8-linked pyrrolbenzodiazepine (PBD)-biaryl conjugates with femptomolar <i>in vitro</i> cytotoxicity and <i>in vivo</i> antitumour activity in mouse models of pancreatic and breast cancer.. <i>Cancer Research</i> , 2013, 73, 1129-1129.	0.4	5
79	CD49d Is The Strongest Flow Cytometry-Based Predictor Of Overall Survival In Chronic Lymphocytic Leukemia. <i>Blood</i> , 2013, 122, 672-672.	0.6	2
80	Abstract 697: Synthesis and biological evaluation of 2,4,5-substituted pyrimidines as highly selective CDK9 inhibitors for cancer treatment.. , 2013, , .		0
81	Characterization Of a Novel In Vitro Circulation System Designed To Model The Migration Of Primary CLL Cells Across The Vascular Endothelium. <i>Blood</i> , 2013, 122, 667-667.	0.6	0
82	Lymph Node Derived CLL Cells Have a More Activated Phenotype and Better Antigen Presentation Capabilities Compared To Those From The Peripheral Blood. <i>Blood</i> , 2013, 122, 4119-4119.	0.6	10
83	Longitudinal Analysis Reveals Telomere Length Maintenance In CLL B-Cells But Marked Erosion In CLL Patient T-Cells. <i>Blood</i> , 2013, 122, 1617-1617.	0.6	0
84	Expansion of a CD8+PD-1+ Replicative Senescence Phenotype in Early Stage CLL Patients Is Associated with Inverted CD4:CD8 Ratios and Disease Progression. <i>Clinical Cancer Research</i> , 2012, 18, 678-687.	3.2	127
85	Interview: â€™Familialâ€™ chronic lymphocytic leukemia. <i>International Journal of Hematologic Oncology</i> , 2012, 1, 27-28.	0.7	0
86	Mimicking the tumour microenvironment: three different co-culture systems induce a similar phenotype but distinct proliferative signals in primary chronic lymphocytic leukaemia cells. <i>British Journal of Haematology</i> , 2012, 158, 589-599.	1.2	45
87	Defining the prognosis of early stage chronic lymphocytic leukaemia patients. <i>British Journal of Haematology</i> , 2012, 156, 499-507.	1.2	44
88	Telomere dysfunction and its role in haematological cancer. <i>British Journal of Haematology</i> , 2012, 156, 573-587.	1.2	51
89	CDK1G, a novel CDK9 inhibitor, is preferentially cytotoxic to cancer cells compared to flavopiridol. <i>International Journal of Cancer</i> , 2012, 130, 1216-1226.	2.3	54
90	Prognostic Relevance of CD49d Expression On B Leukemic Cells in Chronic Lymphocytic Leukemia. Meta-Analysis of Published and unpublished Individual Data From 3146 Patients. <i>Blood</i> , 2012, 120, 3871-3871.	0.6	1

#	ARTICLE	IF	CITATIONS
91	The Hsp90 inhibitor NVP-AUY922-AG inhibits NF- κ B signaling, overcomes microenvironmental cytoprotection and is highly synergistic with fludarabine in primary CLL cells. <i>Oncotarget</i> , 2012, 3, 525-534.	0.8	38
92	Abstract 1348: CD38 regulates homing and engraftment in a mouse model of CLL. , 2012, , .		0
93	CD49d is an independent prognostic marker that is associated with CXCR4 expression in CLL. <i>Leukemia Research</i> , 2011, 35, 750-756.	0.4	60
94	CD38 Regulates Homing and Engraftment of CLL Cells,. <i>Blood</i> , 2011, 118, 3873-3873.	0.6	0
95	Telomere dysfunction and fusion during the progression of chronic lymphocytic leukemia: evidence for a telomere crisis. <i>Blood</i> , 2010, 116, 1899-1907.	0.6	148
96	The role of Bcl-2 family proteins in chronic lymphocytic leukaemia. <i>Leukemia Research</i> , 2010, 34, 837-842.	0.4	84
97	Common variants at 2q37.3, 8q24.21, 15q21.3 and 16q24.1 influence chronic lymphocytic leukemia risk. <i>Nature Genetics</i> , 2010, 42, 132-136.	9.4	223
98	Interaction with Vascular Endothelium Enhances Survival in Primary Chronic Lymphocytic Leukemia Cells via NF- κ B Activation and <i>De novo</i> Gene Transcription. <i>Cancer Research</i> , 2010, 70, 7523-7533.	0.4	88
99	Rel A Is an Independent Biomarker of Clinical Outcome in Chronic Lymphocytic Leukemia. <i>Journal of Clinical Oncology</i> , 2009, 27, 763-769.	0.8	51
100	NF- κ B as a prognostic marker and therapeutic target in chronic lymphocytic leukemia. <i>Future Oncology</i> , 2009, 5, 1027-1037.	1.1	31
101	Acute renal failure as the presenting feature of leukaemic infiltration in chronic lymphocytic leukaemia. <i>Clinical and Experimental Nephrology</i> , 2009, 13, 179-181.	0.7	17
102	Topoisomerase II Inhibitor Voreloxin Causes Cell Cycle Arrest and Apoptosis in Acute Myeloid Leukaemia Cells and Acts in Synergy with Cytarabine.. <i>Blood</i> , 2009, 114, 4152-4152.	0.6	0
103	The Cyclin Dependent Kinase 2, 7 and 9 Inhibitor SNS-032 Has Single Agent Activity in Acute Myeloid Leukaemia Cells and Is Highly Synergistic with Cytarabine.. <i>Blood</i> , 2009, 114, 1059-1059.	0.6	0
104	IgM multiple myeloma: a diagnostic challenge in a patient with coexisting chronic lymphocytic leukaemia. <i>International Journal of Hematology</i> , 2008, 88, 424-427.	0.7	2
105	A genome-wide association study identifies six susceptibility loci for chronic lymphocytic leukemia. <i>Nature Genetics</i> , 2008, 40, 1204-1210.	9.4	329
106	The Novel Nuclear Factor- κ B Inhibitor LC-1 Is Equipotent in Poor Prognostic Subsets of Chronic Lymphocytic Leukemia and Shows Strong Synergy with Fludarabine. <i>Clinical Cancer Research</i> , 2008, 14, 8102-8111.	3.2	44
107	The NF- κ B subunit Rel A is associated with in vitro survival and clinical disease progression in chronic lymphocytic leukemia and represents a promising therapeutic target. <i>Blood</i> , 2008, 111, 4681-4689.	0.6	145
108	Mcl-1 expression has in vitro and in vivo significance in chronic lymphocytic leukemia and is associated with other poor prognostic markers. <i>Blood</i> , 2008, 112, 3807-3817.	0.6	208

#	ARTICLE	IF	CITATIONS
109	The Sequence-Selective DNA Cross-Linking Agent SJG-136 (SG2000, BN2629) Is Highly Potent in Multiple Myeloma Cells and Is Synergistic with Bortezomib. <i>Blood</i> , 2008, 112, 5166-5166.	0.6	0
110	The DNA Crosslinking Agent SJG-136 (SG2000, BN2629) Is Highly Potent in Acute Myeloid Leukaemia and Is Synergistic with Cytarabine. <i>Blood</i> , 2008, 112, 4013-4013.	0.6	0
111	Pharmacological Inhibition of NF-KB Underpins the Strong Synergy Between LC-1 and Fludarabine in Chronic Lymphocytic Leukaemia Cells. <i>Blood</i> , 2008, 112, 380-380.	0.6	0
112	Rel a Is a Novel Prognostic Marker in CLL That Is Independent of VH Gene Mutation Status, CD38 Expression and ZAP-70 Expression. <i>Blood</i> , 2008, 112, 4153-4153.	0.6	0
113	The Parthenolide Derivative LC-1 Is An Effective Single Agent and Is Highly Synergistic with Existing Therapies in Multiple Myeloma.. <i>Blood</i> , 2008, 112, 1708-1708.	0.6	0
114	The effect of immunoglobulinVH gene mutation status and other prognostic factors on the incidence of major infections in patients with chronic lymphocytic leukemia. <i>Cancer</i> , 2006, 107, 1023-1033.	2.0	82
115	Constitutive Nuclear p65 NF-kB Expression Predicts for Spontaneous Apoptosis and In Vitro Sensitivity to Fludarabine in CLL Cells.. <i>Blood</i> , 2006, 108, 4974-4974.	0.6	0
116	Inhibition of Cellular Aminopeptidases as Novel Therapy for AML.. <i>Blood</i> , 2006, 108, 2588-2588.	0.6	0
117	NF Kappa B as a Therapeutic Target in AML.. <i>Blood</i> , 2006, 108, 2587-2587.	0.6	5
118	Integrating Prognostic Markers and Cellular Signaling Identifies More Chronic Lymphocytic Leukemia Patients with Adverse Prognosis.. <i>Blood</i> , 2006, 108, 2782-2782.	0.6	0
119	Common Polymorphism G(-248)A in the Promoter Region of the bax Gene Results in Significantly Shorter Survival in Patients With Chronic Lymphocytic Leukemia Once Treatment Is Initiated. <i>Journal of Clinical Oncology</i> , 2005, 23, 1514-1521.	0.8	69
120	Micro-Array and Protein Analyses Reveal a Preferential Autocrine VEGF Survival Loop in CD38+ Sub-Clones When Compared with CD38 ⁺ Sub-Clones Derived from the Same CLL Patient.. <i>Blood</i> , 2005, 106, 180-180.	0.6	2
121	The Aurora Kinase Inhibitor AZD1152 Causes Perturbation of Cell Cycle Distribution in Cell Lines and Primary AML Samples.. <i>Blood</i> , 2005, 106, 2759-2759.	0.6	2
122	ZAP-70 Expression Is More Predictive Than VH Gene Mutational Status of BCR-Mediated Tyrosine Phosphorylation, NF- κ B Activation and CLL Cell Survival.. <i>Blood</i> , 2005, 106, 2942-2942.	0.6	0
123	The Novel Anti-Leukemic Agent LC-1, Is Preferentially Cytotoxic in CLL Cells Derived from Poor Prognostic Subsets.. <i>Blood</i> , 2005, 106, 2981-2981.	0.6	0
124	The Novel Sequence-Specific DNA Cross-Linking Agent SJG-136 (NSC 694501) Has Potent and Selective In vitro Cytotoxicity in Human B-Cell Chronic Lymphocytic Leukemia Cells with Evidence of a p53-Independent Mechanism of Cell Kill. <i>Cancer Research</i> , 2004, 64, 6750-6755.	0.4	26
125	The vitamin D3 analog EB1089 induces apoptosis via a p53-independent mechanism involving p38 MAP kinase activation and suppression of ERK activity in B-cell chronic lymphocytic leukemia cells in vitro. <i>Blood</i> , 2003, 101, 2454-2459.	0.6	89
126	Flavopiridol Induces Apoptosis in B-cell Chronic Lymphocytic Leukaemia Cells Through a p38 and ERK MAP Kinase-dependent Mechanism. <i>Leukemia and Lymphoma</i> , 2003, 44, 337-342.	0.6	27

#	ARTICLE	IF	CITATIONS
127	Leukemic and Non-Leukemic Lymphocytes from Patients with Li Fraumeni Syndrome Demonstrate Loss of p53 Function, Bcl-2 Family Dysregulation and Intrinsic Resistance to Conventional Chemotherapeutic Drugs But Not Flavopiridol. <i>Cell Cycle</i> , 2003, 2, 52-57.	1.3	21
128	Leukemic and non-leukemic lymphocytes from patients with Li Fraumeni syndrome demonstrate loss of p53 function, Bcl-2 family dysregulation and intrinsic resistance to conventional chemotherapeutic drugs but not flavopiridol. <i>Cell Cycle</i> , 2003, 2, 53-8.	1.3	8
129	Retinoid-induced apoptosis in B-cell chronic lymphocytic leukaemia cells is mediated through caspase-3 activation and is independent of p53, the retinoic acid receptor, and differentiation. <i>European Journal of Haematology</i> , 2002, 69, 227-235.	1.1	13
130	Antisense Oligonucleotides Complementary to Bax Transcripts Reduce the Susceptibility of B-cell Chronic Lymphocytic Leukaemia Cells to Apoptosis in a Bcl-2 Independent Manner. <i>Leukemia and Lymphoma</i> , 2002, 43, 2003-2009.	0.6	7
131	Bcl-2 Antisense Oligonucleotides Enhance the Cytotoxicity of Chlorambucil in B-Cell Chronic Lymphocytic Leukaemia Cells. <i>Leukemia and Lymphoma</i> , 2001, 42, 491-498.	0.6	32
132	Flavopiridol circumvents Bcl-2 family mediated inhibition of apoptosis and drug resistance in B-cell chronic lymphocytic leukaemia. <i>British Journal of Haematology</i> , 2001, 114, 70-77.	1.2	53
133	Antisense-mediated suppression of Bcl-2 highlights its pivotal role in failed apoptosis in B-cell chronic lymphocytic leukaemia. <i>British Journal of Haematology</i> , 1999, 107, 611-615.	1.2	73
134	Elevated Bcl-2/Bax Are a Consistent Feature of Apoptosis Resistance in B-cell Chronic Lymphocytic Leukaemia and Are Correlated with <i>In Vivo</i> Chemoresistance. <i>Leukemia and Lymphoma</i> , 1998, 28, 355-361.	0.6	100
135	REGULATION OF CLINICAL CHEMORESISTANCE BY bcl-2 AND BAX ONCOPROTEINS IN B-CELL CHRONIC LYMPHOCYTIC LEUKAEMIA. <i>British Journal of Haematology</i> , 1996, 95, 513-517.	1.2	112
136	Enantioselectivity of aromatase inhibitors: Substituted 3-(4-aminophenyl)pyrrolidine-2,5-diones. <i>Chirality</i> , 1995, 7, 376-380.	1.3	5
137	Racemisation of drug enantiomers by benzylic proton abstraction at physiological pH. <i>Chirality</i> , 1994, 6, 400-404.	1.3	20